206 related articles for article (PubMed ID: 26887886)
1. Abatacept experience in steroid and rituximab-resistant focal segmental glomerulosclerosis.
Jayaraman VK; Thomas M
BMJ Case Rep; 2016 Feb; 2016():. PubMed ID: 26887886
[TBL] [Abstract][Full Text] [Related]
2. A partial response to abatacept in a patient with steroid resistant focal segmental glomerulosclerosis.
Soyaltın E; Demir BK; Alparslan C; Çamlar SA; Alaygut D; Yavaşcan Ö; Mutlubaş F
Turk J Pediatr; 2020; 62(4):663-667. PubMed ID: 32779421
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of Recurrent Focal Segmental Glomerulosclerosis After Transplantation in Children: A Single-Center Experience.
Alhasan KA; Alherbish A; Osman A; Kari JA; Almojalli H
Transplant Proc; 2019 Mar; 51(2):517-521. PubMed ID: 30879580
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Focal Segmental Glomerulosclerosis and Abatacept: Case Report.
Alkandari O; Nampoory N; Nair P; Atta A; Zakaria Z; Mossad A; Yagan J; Al-Otaibi T
Exp Clin Transplant; 2016 Aug; 14(4):456-9. PubMed ID: 25432003
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis.
Heering P; Braun N; Müllejans R; Ivens K; Zäuner I; Fünfstück R; Keller F; Krämer BK; Schollmeyer P; Risler T; Grabensee B;
Am J Kidney Dis; 2004 Jan; 43(1):10-8. PubMed ID: 14712422
[TBL] [Abstract][Full Text] [Related]
6. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.
Kolonko A; Piecha G; Więcek A
Transplant Proc; 2016 Nov; 48(9):3092-3094. PubMed ID: 27932154
[TBL] [Abstract][Full Text] [Related]
7. Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis.
Wee Leng G; Mustafar R; Kamaruzaman L; Mohd R; Cader RA; Wei Yen K; Kiew Bing P
Acta Med Indones; 2018 Jul; 50(3):237-243. PubMed ID: 30333274
[TBL] [Abstract][Full Text] [Related]
8. [Steroid-resistant focal segmental glomerulosclerosis treated with cascade plasmafiltration and rituximab].
Tatangelo P; Londrino F; Di Vasta G; Guido G; Centi A; Dominijanni S; Bernabei E; Caramiello MS; Di Franco D; Palumbo R
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786187
[TBL] [Abstract][Full Text] [Related]
9. Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide.
Hari P; Bagga A; Jindal N; Srivastava RN
Pediatr Nephrol; 2001 Nov; 16(11):901-5. PubMed ID: 11685598
[TBL] [Abstract][Full Text] [Related]
10. Focal segmental glomerulosclerosis complicating solitary kidney.
Oshiro Y; Umena S; Noda M
Clin Exp Nephrol; 2009 Feb; 13(1):81-4. PubMed ID: 18688570
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.
Lee HY; Kim HS; Kang CM; Kim SG; Kim MJ
Clin Nephrol; 1995 Jun; 43(6):375-81. PubMed ID: 7554521
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis.
Chiou YY; Lee YC; Chen MJ
Curr Med Res Opin; 2017 Aug; 33(8):1389-1399. PubMed ID: 28436233
[TBL] [Abstract][Full Text] [Related]
13. Advanced therapeutics in focal and segmental glomerulosclerosis.
Liu Y; Shi Y; Ren R; Xie J; Wang W; Chen N
Nephrology (Carlton); 2018 Oct; 23 Suppl 4():57-61. PubMed ID: 30298667
[TBL] [Abstract][Full Text] [Related]
14. Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept
.
Dado D; Parikh S; Ayoub I; Rovin B; Nadasdy T; Hebert L
Clin Nephrol; 2018 May; 89(5):376-380. PubMed ID: 29249233
[TBL] [Abstract][Full Text] [Related]
15. Steroid resistant focal segmental glomerulosclerosis: effect of arterial hyalinosis on outcome: single center study.
Soliman AR; Maamoun H; Soliman H; Ahmed RM
Rom J Intern Med; 2021 Jun; 59(2):127-133. PubMed ID: 33565308
[No Abstract] [Full Text] [Related]
16. T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS.
Chan CY; Liu ID; Resontoc LP; Ng KH; Chan YH; Lau PY; Than M; Jordan SC; Lam KP; Yeo WS; Yap HK
Clin J Am Soc Nephrol; 2016 Aug; 11(8):1360-1368. PubMed ID: 27269610
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in treatment of collapsing FSGS-A case series.
Girimaji N; Bharati J; Nada R; Rathi M; Kohli HS; Ramachandran R
Nephrology (Carlton); 2021 Feb; 26(2):134-141. PubMed ID: 32662534
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study.
Goumenos DS; Tsagalis G; El Nahas AM; Shortland JR; Davlouros P; Vlachojannis JG; Brown CB
Nephron Clin Pract; 2006; 104(2):c75-82. PubMed ID: 16785738
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment With Abatacept in Recurrent Focal Segmental Glomerulosclerosis After Kidney Transplant.
Shah Y; Almeshari K; Aleid H; Broering D; Alahmadi I; Ali T
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):178-180. PubMed ID: 30777550
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis.
Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Suzuki Y; Ohara S; Hosoya M
Pediatr Int; 2016 Mar; 58(3):219-223. PubMed ID: 26275234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
